TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet and Prevention of Ischemic Heart Disease: a Translational Approach
Brief Summary: The objective of this study is to test the effect of substitution dietary guidelines that are specifically aimed at the prevention of ischemic heart disease (IHD) on the dietary intake in the general Danish population.


Options:
A: Arm Label: AARP; Type: N/A; Interventions: N/A
B: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
C: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet and Prevention of Ischemic Heart Disease: a Translational Approach
Brief Summary: The objective of this study is to test the effect of substitution dietary guidelines that are specifically aimed at the prevention of ischemic heart disease (IHD) on the dietary intake in the general Danish population.


Options:
A: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
C: Arm Label: Exercise under observation; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and exercise under observation | Arm Label: General advice on exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and general advice on exercise | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and exercise under observation; Assigned to Arm(s): Exercise under observation | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and general advice on exercise; Assigned to Arm(s): General advice on exercise
D: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet and Prevention of Ischemic Heart Disease: a Translational Approach
Brief Summary: The objective of this study is to test the effect of substitution dietary guidelines that are specifically aimed at the prevention of ischemic heart disease (IHD) on the dietary intake in the general Danish population.


Options:
A: Arm Label: low-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-fat diet | Arm Label: moderate-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: moderate-fat diet | Arm Label: high-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: high-fat diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate-fat diet; Assigned to Arm(s): moderate-fat diet | Intervention Type: BEHAVIORAL; Name: high-fat diet; Assigned to Arm(s): high-fat diet
B: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
C: Arm Label: low fat diet; Type: EXPERIMENTAL; Interventions: Other: Weight-loss diet strategy (+) exercise (PA), Other: weight loss (-) exercise (PA) | Arm Label: low carb diet; Type: EXPERIMENTAL; Interventions: Other: Weight-loss diet strategy (+) exercise (PA), Other: weight loss (-) exercise (PA) | Intervention Type: OTHER; Name: Weight-loss diet strategy (+) exercise (PA); Assigned to Arm(s): low carb diet, low fat diet | Intervention Type: OTHER; Name: weight loss (-) exercise (PA); Assigned to Arm(s): low carb diet, low fat diet
D: Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Arm Label: Dairy Protein; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Arm Label: High Dairy Protein; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Aerobic and Resistance, Behavioral: Dietary - Caloric Restriction | Intervention Type: BEHAVIORAL; Name: Exercise - Aerobic and Resistance; Assigned to Arm(s): Control, Dairy Protein, High Dairy Protein | Intervention Type: BEHAVIORAL; Name: Dietary - Caloric Restriction; Assigned to Arm(s): Control, Dairy Protein, High Dairy Protein

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study
Brief Summary: The combined spinal epidural (CSE) technique has become increasingly popular for labor pain because of its rapid onset and superior first stage analgesia. However, increased risk for early profound fetal bradycardia (EPFB) following CSE continues to be a concern. Various factors are implicated in the etiology of EPFB but the cause is unknown. Ephedrine administration prior to CSE analgesia may help reduce the risk of EPFB, but to date, nobody has studied the impact of a single dose of intravenous (IV) ephedrine given at the time of CSE administration during labor. The purpose of this study is to measure the incidence of EPFB after combined spinal epidural analgesia using standard definitions. The incidence of EPFB will be compared between patients who receive prophylactic ephedrine or placebo at the time of CSE placement.


Options:
A: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B
C: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine
D: Arm Label: ondansetron; Type: EXPERIMENTAL; Interventions: Drug: ondansetron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ondansetron; Assigned to Arm(s): ondansetron | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study
Brief Summary: The combined spinal epidural (CSE) technique has become increasingly popular for labor pain because of its rapid onset and superior first stage analgesia. However, increased risk for early profound fetal bradycardia (EPFB) following CSE continues to be a concern. Various factors are implicated in the etiology of EPFB but the cause is unknown. Ephedrine administration prior to CSE analgesia may help reduce the risk of EPFB, but to date, nobody has studied the impact of a single dose of intravenous (IV) ephedrine given at the time of CSE administration during labor. The purpose of this study is to measure the incidence of EPFB after combined spinal epidural analgesia using standard definitions. The incidence of EPFB will be compared between patients who receive prophylactic ephedrine or placebo at the time of CSE placement.


Options:
A: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
B: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine
C: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making in Parents of Children With Head Trauma: Head CT Choice
Brief Summary: The investigators will test the impact of a decision aid, Head CT Choice, to determine if its use improves parents' knowledge and engagement in decision making and safely decreases healthcare utilization in children presenting to the emergency department with blunt head trauma.


Options:
A: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: video | Intervention Type: OTHER; Name: video; Assigned to Arm(s): 2
C: Arm Label: Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Head CT Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Head CT Decision Aid; Assigned to Arm(s): Decision Aid
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Patient video decision aid & telephone coaching | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Printed educational brochure | Intervention Type: BEHAVIORAL; Name: Patient video decision aid & telephone coaching; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Printed educational brochure; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a French Maritim Pine Bark Extract Oligopin® on Blood Pressure: Double Blind, Crossover, Placebo-controlled Nutrition Intervention Trial
Brief Summary: The objective of the study is to evaluate the effect of consumption of a food supplement rich in procyanidins extracted from the bark of French pine, Oligopin®, on blood pressure of people with mild / moderate degree of hypertension. Furthermore, the effect Oligopin® consumption on markers involved in the development of hypertension, and endothelial function in key enzymes that regulate blood pressure, inflammation and oxidation are considered. Also, try to advance the understanding of the molecular mechanisms that regulate blood pressure.


Options:
A: Arm Label: Verum; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Verum | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Verum; Assigned to Arm(s): Verum | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Product one; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Product two; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oligopin® | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Product one | Intervention Type: DIETARY_SUPPLEMENT; Name: Oligopin®; Assigned to Arm(s): Product two
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pine Bark Extract (Flavangenol®) | Arm Label: Pine Bark Extract; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pine Bark Extract (Flavangenol®) | Intervention Type: DRUG; Name: Pine Bark Extract (Flavangenol®); Assigned to Arm(s): Pine Bark Extract, Placebo
D: Arm Label: Pycnogenol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pycnogenol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DIETARY_SUPPLEMENT; Name: Pycnogenol; Assigned to Arm(s): Pycnogenol | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Brief Summary: The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.


Options:
A: Arm Label: BEZ235; Type: EXPERIMENTAL; Interventions: Drug: BEZ235 | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: BEZ235; Assigned to Arm(s): BEZ235 | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: Arm I (octreotide acetate and bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate | Arm Label: Arm II (octreotide acetate and recombinant interferon alfa-2b); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate, Biological: Recombinant Interferon Alfa-2b | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: DRUG; Name: Octreotide Acetate; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Arm II (octreotide acetate and recombinant interferon alfa-2b)
C: Arm Label: Surufatinib; Type: EXPERIMENTAL; Interventions: Drug: Surufatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Surufatinib; Assigned to Arm(s): Surufatinib | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections
Brief Summary: Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children will be randomized to randomized to urgent (\<48 hours) versus early antiretroviral therapy (7-14 days). This trial will be unblinded.

Population: Hospitalized HIV-1 infected children who are antiretroviral therapy (ART) naïve ≤ 12 years of age.

Sample size: 360 children will be randomized (180 per arm).

Treatment: All infants will be treated with ART according to World Health Organization (WHO) and Kenyan national guidelines.

Study duration: Enrollment into the study will occur over the course of 36-48 months and each infant will be routinely followed for a maximum of 6 months.

Study site: Kenyan hospitals.

Primary hypothesis:

HIV-1 infected children hospitalized with severe co-infection either may be unsalvageable due to too far advanced immunosuppression/co-infection or may benefit from urgent ART.

Secondary hypotheses:

Urgent ART during an acute infection could potentially result in increased risk of immune reconstitution inflammatory syndrome (IRIS) or drug toxicities/interactions.

Specific aims:

1. To compare the 6 month all-cause mortality rate, incidence of immune reconstitution inflammatory syndrome (IRIS), and incidence of drug toxicity in HIV-1 infected children (≤ 12 years old) presenting to hospital with a serious infection randomized to urgent (\<48 hours) versus early ART (7-14 days).
2. To determine co-factors for mortality, IRIS, and drug toxicity. Potential cofactors will include: baseline weight-for-age, height-for-age, weight-for-height (Z-scores), CD4, HIV-1 RNA, type of co-infection, age, rate of viral load and CD4 change following ART, immune activation markers, pathogen and HIV-1 specific immune responses.

Secondary aim: To determine etiologies of IRIS and to compare immune reconstitution to HIV, TB, EBV and CMV following ART overall and in each trial arm.


Options:
A: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
B: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART
C: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supervised Obesity Reduction Trial for AF Ablation Patients
Brief Summary: Study hypothesis:

Weight reduction in obese patients with atrial fibrillation. Obese patients benefit from an obesity treatment after atrial fibrillation ablation.

Study design:

A prospective randomized, open-label clinical trial.


Options:
A: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
B: Arm Label: 10 mg Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): 10 mg Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention group | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group
D: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A

Answer: C